Ngf Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
.infobox .infobox-gene
| Gene Symbol | NGF |
|---|---|
| Gene Name | Nerve Growth Factor |
| Chromosome | 1p13.1 |
| NCBI Gene ID | 4800 |
| OMIM ID | 162030 |
| Ensembl ID | ENSG00000167136 |
| UniProt ID | P01138 |
| Associated Diseases | Alzheimer's Disease, Peripheral Neuropathy, Charcot-Marie-Tooth Disease, Hereditary Sensory and Autonomic Neuropathy |
| --- | --- |
| Categories | Neurotrophin Signaling, Neuroprotection, Synaptic Plasticity |
Nerve Growth Factor (NGF) is the founding member of the neurotrophin family of growth factors and plays a fundamental role in the development, maintenance, and survival of neurons throughout the nervous system. Discovered in the 1950s by Rita Levi-Montalcini and Stanley Cohen, NGF was the first growth factor ever characterized and remains one of the most extensively studied neurotrophic molecules. NGF exerts its effects by binding to two distinct classes of cell surface receptors: the high-affinity TrkA receptor (encoded by NTRK1), which mediates the classic neurotrophic effects including neuronal survival, differentiation, and synaptic plasticity; and the low-affinity p75^NTR receptor, which modulates TrkA signaling and can also mediate apoptosis in the absence of TrkA. In the central nervous system, NGF is critically important for the survival and function of basal forebrain cholinergic neurons, which degenerate early in Alzheimer's disease. Dysregulation of NGF signaling has been implicated in numerous neurodegenerative disorders, making it an important therapeutic target.
Nerve Growth Factor (NGF) is a neurotrophin that is essential for the survival and development of sympathetic and sensory neurons. NGF binds to TrkA (NTRK1) receptors, activating downstream signaling cascades including PI3K/AKT and MAPK pathways that promote neuronal survival, differentiation, and synaptic plasticity. In the central nervous system, NGF plays critical roles in cholinergic neuron function, and its dysregulation is implicated in Alzheimer's disease pathogenesis.
NGF exerts its effects through two distinct receptor systems:
TrkA (NTRK1): High-affinity tyrosine kinase receptor that mediates the classic neurotrophic effects of NGF. TrkA activation triggers:
p75^NTR: Low-affinity receptor that can either enhance or inhibit TrkA signaling depending on context. The p75^NTR receptor can:
NGF signaling is critically impaired in Alzheimer's disease (AD). The cholinergic neurons of the basal forebrain, which depend on NGF for survival, show early degeneration in AD[3]. Key mechanisms include:
NGF deficiency plays a central role in diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. NGF supplementation has shown promise in clinical trials for reducing neuropathic pain symptoms[4].
Loss-of-function mutations in NGF cause hereditary sensory and autonomic neuropathy type V (HSAN5), characterized by insensitivity to pain, anhidrosis, and developmental delays[5].
Several therapeutic strategies targeting NGF signaling are in development:
The NGF gene is associated with several neurodegenerative and neurological disorders. Specific mutations cause distinct clinical phenotypes, and common variants may influence disease risk.
The study of Ngf Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] PI3K/AKT pathway in NGF signaling (2020)
[2] p75^NTR and sortilin in NGF transport (2019)
[3] Cholinergic degeneration in AD (2018)
[4] NGF for peripheral neuropathy (2021)
[5] HSAN5 disease mechanisms (2017)
[6] NGF clinical trials in AD (2016)
[7] AAV-NGF gene therapy (2019)